Robert Iannone Sells 7,159 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $168.26, for a total transaction of $1,204,573.34. Following the transaction, the executive vice president directly owned 72,628 shares of the company’s stock, valued at $12,220,387.28. This trade represents a 8.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jazz Pharmaceuticals Trading Down 2.5%

Shares of JAZZ traded down $4.44 during mid-day trading on Wednesday, reaching $176.08. The company had a trading volume of 1,840,608 shares, compared to its average volume of 943,982. The stock has a market cap of $10.70 billion, a price-to-earnings ratio of -26.16, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. The firm has a fifty day simple moving average of $136.90 and a 200-day simple moving average of $121.57. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same period in the prior year, the firm posted $6.54 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JAZZ. JPMorgan Chase & Co. decreased their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $195.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC lifted its holdings in Jazz Pharmaceuticals by 56.2% in the 1st quarter. CWM LLC now owns 1,259 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 453 shares in the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Jazz Pharmaceuticals by 269.5% during the first quarter. Y Intercept Hong Kong Ltd now owns 9,721 shares of the specialty pharmaceutical company’s stock valued at $1,207,000 after acquiring an additional 7,090 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter worth about $10,900,000. KLP Kapitalforvaltning AS increased its position in shares of Jazz Pharmaceuticals by 1.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock worth $2,148,000 after acquiring an additional 300 shares during the last quarter. Finally, Readystate Asset Management LP lifted its stake in shares of Jazz Pharmaceuticals by 7.7% in the first quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after acquiring an additional 1,635 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.